Johnson & Johnson could face generic competition for its blockbuster prostate cancer therapy Zytiga (abiraterone acetate) as early as October now that the composition and method of use patent covering the drug has been found unpatentable by the US Patent and Trademark Office's Patent Trial and Appeal Board.
On Jan. 17, the Board issued final written decisions in five inter partes review (IPR) cases challenging patent No
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?